RxDoctor Payments Data

Diana Escobedo, MD

Family Medicine · Horizon City, TXNPI 1104278795

Payments from drug & device makers

$2,164in general payments, 2019–2025

Across 78 payments — averaging $27.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$818
  • AstraZeneca$629
  • Lilly USA, LLC$151
  • Exact Sciences$114
  • AbbVie$107
  • Novo Nordisk$88
  • plus $257 from 6 others

What the payments were for

  • Food & beverage$2,14399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,164 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,394
Medicare patients
13
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol100$126,866
OzempicSemaglutide81$125,582
TrulicityDulaglutide67$79,366
MounjaroTirzepatide41$42,585
JanuviaSitagliptin Phosphate24$32,038
JardianceEmpagliflozin16$26,598
XareltoRivaroxaban16$17,332
EliquisApixaban14$16,911
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$8,925
VascepaIcosapent Ethyl16$5,100
Rosuvastatin Calcium314$3,583
Atorvastatin Calcium235$2,967
Varenicline Tartrate12$2,808
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,440
Tamsulosin Hcl112$1,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$629$126,866100 claims
Novo NordiskOzempic$88$125,58281 claims
Lilly USA, LLCTrulicity, Mounjaro$151$121,951108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Horizon City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →